Lymphovascular invasion (LVI) is a prognostic factor in many types of human malignancies, including pancreatic ductal adenocarcinoma (PDAC). However, the prognostic significance of LVI in patients with PDAC who have received neoadjuvant therapy and pancreaticoduodenectomy is unclear. In this study, we analyzed LVI in 212 patients who had received neoadjuvant chemoradiation and subsequent pancreaticoduodenectomy at our institution between January 1999 and December 2007. LVI was present in 61.8% (131/212) of the patients. Of the 131 patients who were positive for LVI, 67 (31.6%) had tumor invasion into lymphovascular spaces without muscle layer (nonmuscular lymphovascular spaces), and 64 (30.2%) had tumor invasion into muscular vessels. Tumor invasion into muscular vessels correlated with higher frequencies of positive resection margin, lymph node metastasis, and locoregional/distant recurrence. Patients with tumor invasion into muscular vessels had significantly shorter disease-free survival and overall survival than did patients who had no LVI or who had tumor invasion of nonmuscular lymphovascular spaces (P<0.01). Tumor invasion into muscular vessels is an independent prognostic factor in patients with PDAC who have received neoadjuvant therapies. Our results showed that tumor invasion into muscular vessels plays an important role in the progression of PDAC and in predicting prognosis in this group of patients.
P ancreatic cancer is the fourth leading cause of cancer death in the United States and has a poor prognosis. Surgical resection remains the only hope for curative therapy for patients with pancreatic cancer. However, most patients with pancreatic ductal adenocarcinoma (PDAC) present late with locoregional advanced disease or metastatic dissemination and are not surgically resectable. 17 Even in patients with PDAC who have undergone surgical resection, the disease commonly recurs, and the long-term survival rate is only 10% to 20%. 16, 26 This is partly because of high frequencies of subclinical metastases at the time of diagnosis and surgery that are not detectable by radiologic imaging. Previous studies have shown that postoperative adjuvant chemoradiation improves survival and delays tumor recurrence in patients with PDAC who have undergone pancreatectomy. 7, 16, 22, 24, 25 However, the overall survival (OS) for patients with PDAC has not changed significantly over the last 4 decades, despite significant improvements in surgical oncology and perioperative mortality associated with pancreatectomy. 12 Recently, preoperative neoadjuvant chemoradiation therapies have been increasingly used to treat patients with potentially resectable PDAC. In a phase II trial of neoadjuvant gemcitabinebased chemoradiation of 86 patients with PDAC, who were treated with 7 weekly intravenous (IV) infusions of gemcitabine (400 mg/m 2 IV over 30 min) plus radiation therapy (30 Gy in 10 fractions over 2 wk), Evans et al 10 reported a median survival of 34 months and 36% 5-year survival rate for the 64 patients who underwent pancreaticoduodenectomy (PD), which was better than the survival rates of the 22 patients who did not undergo PD (median survival of 7 mo and 0% 5-year survival). Similar results have been reported from another phase II trial of 79 patients who had received the preoperative gemcitabine and cisplatin chemotherapy in addition to gemcitabine-based chemoradiation. In this trial, the 52 patients who completed neoadjuvant therapy and underwent PD had better survival (median, 31 mo) compared with the 27 patients who did not undergo surgical resection (median, 10.5 mo). 27 These data suggest that neoadjuvant chemoradiation is safe and may improve survival in patients with PDAC who undergo PD. 13 Previous studies have shown that lymph node metastasis, tumor size, tumor differentiation, resection margin status, perineural and lymphovascular invasion (LVI), and the American Joint Committee on Cancer (AJCC) tumor stage correlate independently with survival in patients with PDAC who undergo PD. 1, 3, 4, 6, 11, 12 However, most previous studies are based on patient populations with PDAC who did not receive preoperative neoadjuvant therapy. Little is known about the prognostic factors in patients with PDAC who received neoadjuvant chemoradiation and PD. In our previous studies, we demonstrated that posttherapy pathologic stage, lymph node status, number of positive regional lymph nodes, and the histologic grading of residual viable tumor are independent prognostic factors in this group of patients. 5, 9 The prognostic significance of LVI in patients with PDAC who received neoadjuvant therapies and underwent PD is unclear. In this study, we evaluated LVI by reviewing the archival hematoxylin and eosin (H&E)stained slides from 212 patients who had received neoadjuvant chemoradiation therapy and undergone PD at our institution. The results of LVI were correlated with survival and other clinical and pathologic parameters. Our data showed that tumor invasion into muscular vessels is an important prognostic factor and an independent predictor of overall and disease-free survival (DFS) in this group of patients.
MATERIALS AND METHODS

Patient Population
Our study population consisted of 212 patients with PDAC who had received neoadjuvant chemoradiation therapy and undergone PD at our institution from January 1999 to December 2007. The neoadjuvant therapy regimens in this study population included 5 different treatment groups: group 1, which received fluoropyrimidinebased chemoradiation, comprising 39 patients (18.4%); group 2, which received gemcitabine-based chemoradiation, comprising 66 patients (31.1%); group 3, which received systemic chemotherapy followed by gemcitabine-based chemoradiation, comprising 70 patients (33.0%); group 4, which received systemic chemotherapy followed by fluoropyrimidine-based chemoradiation, comprising 32 patients (15.1%); and group 5, which received systemic chemotherapy alone, comprising 5 patients (2.4%). Among these patients, 136 (64.2%; groups 2 and 3) were treated on the basis of previously published protocols. 10, 27 After completion of neoadjuvant therapy, all patients underwent restaging evaluation, and PD was performed only on patients with resectable disease, who did not have disease progression, metastasis, or contraindications to major abdominal surgery. Patients who underwent distal pancreatectomy and those who underwent PD for other types of pancreatic tumors were excluded. There were 124 male and 88 female patients with ages ranging from 39 to 85 years (median, 63 y). The study was approved by the Institutional Review Board of the University of Texas M.D. Anderson Cancer Center.
Pathologic Examination
The archival H&E-stained slides from all cases were uniformly reviewed by a pathologist (D.C.). In this study, we classified LVI into 2 types: tumor invasion into lymphovascular spaces lined by endothelium without muscle layer (nonmuscular LVS) and tumor invasion into muscular vessels, which was defined by histology as the presence of tumor cells in the lumen of vascular structures containing circumferential smooth muscle layers. If both tumor invasion into muscular vessels and nonmuscular LVS were present, the case was considered as positive for tumor invasion into muscular vessels. Representative micrographs of tumor invasion into nonmuscular LVS and tumor invasion into muscular vessels are shown in Figure 1 . In the cases with questionable LVI or to determine the type of vessels with tumor invasion, the H&E-stained slides were evaluated by 2 additional gastrointestinal pathologists (H.W. and A.R.). Consensus among the 3 pathologists for the presence or absence of LVI and tumor invasion into nonmuscular LVS or into muscular vessels was obtained and used for statistical analysis. The presence of tumor cell invasion into the vascular wall, but no tumor cells in the lumen, was also considered as negative for LVI or for tumor invasion into muscular vessels. In addition, other histologic parameters, including tumor size, differentiation, lymph node status, and margin status by histology were also reviewed and recorded. If any of the resection margins of a PD specimen was involved by PDAC, the case was classified as margin positive. The total number of slides reviewed from the pancreas and tumor ranged from 3 to 45 (the mean number of slides: 14). The posttherapy pathologic staging was grouped according to the AJCC Cancer Staging Manual, 7th edition. 8 The extent of residual viable tumor cells in posttherapy PD specimens was graded as previously described: response group 1 (no viable tumor or less than 5% of viable tumor cells) and response group 2 (5% or more viable tumor cells). 5
Clinical Follow-up and Statistical Analysis
Patient clinical and follow-up information through December of 2009 was extracted from a prospectively maintained database. The clinical and follow-up data from all patients have been verified by an independent review of patient medical records and the US Social Security Index. Local/regional or distant recurrence at first site or sites was classified on the basis of computed tomography scans as previously defined. 5 Chi-square analysis or the Fisher exact test was used to compare categorical data, and analysis of variance was used to compare continuous variables. The Kaplan-Meier method was used to construct survival curves, and the log-rank test was used to evaluate the statistical significance of differences in survival. DFS was calculated as the time from the date of surgery to the date of first recurrence after surgery (in patients with recurrence) or to the date of last follow-up (in patients without recurrence). OS was calculated as the time from the date of diagnosis to the date of death or last follow-up (if death did not occur). Univariate Cox regression analysis was used to examine the prognostic significance of LVI and other clinicopathologic characteristics. After interactions between the variables were examined, a backward stepwise procedure was used to derive the best-fitting model for multivariate analysis using Cox proportional hazards models. All statistical analyses were carried out using Statistical Package for Social Sciences software (for Windows 12.0, SPSS Inc., Chicago, IL). A 2-sided significance level of 0.05 was used for all statistical analyses.
RESULTS
Correlation of LVI With Clinicopathologic Parameters
LVI was identified in 131 (61.8%) of 212 patients. Among the patients who had LVI, 67 (31.6%) patients had tumor invasion into nonmuscular LVS, and 64 (30.2%) had tumor invasion into muscular vessels. The correlations of tumor invasion into nonmuscular LVS and muscular vessels in PD with other clinicopathologic features have been summarized in Table 1 . Compared with patients who had no LVI, patients who had tumor invasion into nonmuscular LVS showed a higher frequency of lymph node metastasis and higher AJCC stage (P<0.01). However, the presence of tumor invasion into nonmuscular LVS in PD specimens had no significant correlations with other clinicopathologic parameters (P>0.05). In patients positive for LVI, the presence of tumor invasion into muscular vessels correlated significantly with higher frequencies of positive resection margin (P = 0.03), lymph node metastasis (P<0.001), posttherapy pathologic tumor stage (ypT, P = 0.007), posttherapy AJCC stage (P<0.001), and worse tumor response to therapy (P = 0.01) compared with those patients who were negative for LVI (Table 1) . During follow-up, 58/64 (90.6%) patients who had tumor invasion into muscular vessels developed local recurrence or distant metastasis; which was significantly higher than 58.0% (47/81) for the patients who had no LVI or 67.2% (45/67) in those who had tumor invasion into nonmuscular LVS (P = 0.002). Patients with tumor invasion into muscular vessels also had a higher frequency of positive resection margins than did those patients who had tumor invasion into nonmuscular LVS (P = 0.04). There were no significant differences in other clinicopathologic parameters between the group with tumor invasion into muscular vessels and those with tumor invasion into nonmuscular LVS (P>0.05). These data suggest that the presence of tumor invasion into muscular vessels in patients with PDAC is associated with more aggressive behavior of the tumor.
Correlation of LVI With Survival
The median follow-up of all patients was 33.2 months, ranging from 7.6 to 122.3 months. Patients with tumor invasion into muscular vessels had a median DFS of 9.0 months [95% confidence interval (CI), 7.8-10.2 mo], which was significantly shorter than the median DFS of 26.0 months (95% CI, 15.0-37.1 mo) in patients who had no LVI (P<0.001) and the median DFS of 12.8 months (95% CI, 7.7-17.8 mo) in patients who had tumor invasion into nonmuscular LVS (P = 0.006) ( Fig. 2A) . Patients with tumor invasion into muscular vessels also had significantly shorter OS compared with patients who were negative for LVI or who had tumor invasion into nonmuscular LVS (Fig. 2B) . The median OS for patients who had tumor invasion into muscular vessels was 24.0 months (95% CI, 19.0-29.0 mo) compared with median OS of 47.9 months (95% CI, 28.6-67.2 mo) for patients who had no LVI (P<0.001) and median OS of 39.5 months (95% CI, 29.2-49.7 mo) for patients with tumor invasion into nonmuscular LVS (P = 0.002, Fig. 2B ). Although patients with tumor invasion into nonmuscular LVS had shorter DFS and OS compared with those patients who had no LVI, the differences in DFS and OS between these 2 groups were not statistically significant (P>0.05, Fig. 2 ). Patients with tumor invasion into muscular vessels had shorter DFS and OS compared with those who had no tumor invasion into muscular vessels (Figs. 3A, B ). The median DFS and OS for patients who had tumor invasion into muscular vessels were 9.0 months (95% CI, 7.8-10.2 mo) and 24.0 months (95% CI, 19.0-29.0 mo), respectively, compared with the median DFS of 19.3 months (95% CI, 12.1-26.5 mo, P<0.0001) and median OS of 40.5 months (95% CI, 28.6-52.4 mo, P<0.0001) for patients who had no tumor invasion into muscular vessels.
The results from univariate Cox regression analysis for DFS and OS are shown in Table 2 . Both DFS and OS were significantly associated with lymph node metastasis, posttherapy AJCC tumor stage, and tumor invasion into muscular vessels (P<0.05). In addition, OS was also associated with resection margin status (P = 0.008) and ypT (P = 0.02). There was no significant association of either DFS or OS with gender, intraoperative blood loss, neoadjuvant therapy regimens, tumor differentiation, or tumor size (P>0.05, Table 2 ). In multivariate analysis, the presence of tumor invasion into muscular vessels was an independent prognostic factor for both OS and DFS (P<0.001, Table 3 ). 
DISCUSSION
In this study, we examined LVI in PD specimens from 212 patients with PDAC who had received neoadjuvant therapy. We found that the presence of tumor invasion into nonmuscular LVS or tumor invasion into muscular vessels correlated with lymph node metastasis and posttherapy AJCC stage. In addition, we found that tumor invasion into muscular vessels was also correlated Patients with tumor invasion into muscular vessels had shorter DFS and OS compared with those who were negative for LVI or those who had tumor invasion into nonmuscular LVS. with higher frequencies of positive resection margin, locoregional and distant recurrence, and higher ypT stage. Tumor invasion into muscular vessels correlated sig-nificantly with both DFS and OS and was an independent prognostic factor for both DFS and OS in multivariate analysis. Therefore, tumor invasion into muscular vessels plays an important role in tumor progression and in predicting the prognosis in patients with PDAC who have received neoadjuvant therapy and PD. Tumor invasion into lymphatic channels and blood vessels is an important pathway by which tumors progress and spread to adjacent and distant tissues or organs and has been shown to be an important prognostic factor in many types of human malignancies. In patients with PDAC who underwent PD first and did not receive neoadjuvant therapy, LVI has been reported in 48% to 92% of the PD specimens. 2, 15 The presence of LVI in PD specimens has been shown to be associated with peritoneal dissemination and worse survival in patients with PDAC who received surgery first but no neoadjuvant therapy. 1, 6, 15 However, the frequency of LVI and its prognostic value in patients with PDAC who received neoadjuvant therapy is largely unknown. In this study, we found that LVI was present in 61.8% of the cases in a cohort of 212 patients with PDAC who had received neoadjuvant therapy and PD. We further subclassified LVI into tumor invasion into nonmuscular LVS and tumor invasion into muscular vessels. Our data showed that tumor invasion into muscular vessels correlated with a higher frequency of positive resection margin, posttherapy pathologic tumor stage, lymph node status, posttherapy AJCC stage, worse tumor response to therapy, and higher risk of locoregional/distant recurrence compared with absence of tumor invasion into muscular vessels in patients with PDAC who had received neoadjuvant therapy. In addition, the presence of tumor invasion into muscular vessels correlated with shorter DFS and OS compared with absence of tumor invasion into muscular vessels. However, we did not observe significant differences in either DFS or OS between patients who had tumor invasion into nonmuscular LVS and those who had no LVI. Using univariate and multivariate analyses, we demonstrated that the presence of tumor invasion into muscular vessels was an independent prognostic factor for both DFS and OS in our patient population. Our findings are consistent with previous reports that show that the presence of LVI is associated with posttherapy pathologic stage and worse 5-year survival rate in patients with gastric and rectal adenocarcinoma who had received neoadjuvant therapy. 18, 21, 23 In a cohort of 297 patients with locally advanced rectal adenocarcinoma who received neoadjuvant therapy, Guillem et al 14 showed that the presence of LVI, along with perineural invasion, tumor response >95%, and lymph node metastasis, was an independent prognostic factor for both DFS and OS in their patient population. Our results suggest that tumor invasion into muscular vessels plays an important role in tumor progression and in predicting prognosis in patients with PDAC who had received neoadjuvant therapy. The shorter survival in our patients with tumor invasion into muscular vessels may be due to the higher incidence of local recurrence and distant metastasis observed in this group of patients compared with those with no LVI or those with tumor invasion into nonmuscular LVS alone.
To evaluate the role of LVI in predicting prognosis in patients with PDAC who did not receive neoadjuvant therapy, we examined lymphovascular involvement and its correlation with survival and clinicopathologic features in 60 consecutive patients who did not receive any form of neoadjuvant therapy before PD (the untreated group) during the same time period at our institution. We found that LVI was present in 47 (78.3%) untreated cases, which is higher than those who had received neoadjuvant therapy (61.8%, P = 0.02). The difference in the frequency of tumor invasion into muscular vessels in the untreated group (24/60, 40.0%) was not statistically significant (P = 0.16) compared with those who had received neoadjuvant therapy (64/212, 30.2%). Similar to our findings in patients who had received neoadjuvant therapy, the presence of LVI correlated with lymph node metastasis in the untreated group (P<0.05, data not shown). In contrast to previous reports that the presence of LVI is associated with peritoneal dissemination and worse survival in patients with PDAC who had received surgery first but no neoadjuvant therapy, 1,6,15 we did not observe significant correlations of LVI or tumor invasion into muscular vessels with other clinicopathologic parameters, DFS, or OS in the untreated group (P>0.05, data not shown). This may be partly due to the highly selective patient population with PDAC who had received neoadjuvant therapy in our treated group, excluding those patients whose tumor had more aggressive clinical behavior during the neoadjuvant chemoradiation treatment.
One weakness of this study is that we evaluated LVI on H&E-stained sections, whereas other studies used immunohistochemical markers for the involvement of lymphatic or blood vessels by tumor cells, such as CD34 and CD31 for blood vessels and podoplanin/D2-40 for lymphatics. 19, 20 However, immunohistochemical staining for either lymphatics or blood vessels is rarely performed for lymphovascular involvement in PD specimens in patients with PDAC during routine histopathology evaluation. In addition, the cases with questionable LVI or tumor invasion into muscular vessels in this study had been reviewed by 2 additional gastrointestinal pathologists, and consensus for the presence or absence of lymphovascular involvement was used for statistical analysis. We believe that our approach is more practical and easily applicable by other pathologists.
In summary, the data presented here show that tumor invasion into muscular vessels correlates with higher frequencies of positive resection margin, lymph node metastasis, and locoregional/distant recurrence in patients with PDAC who have received neoadjuvant therapy and undergone PD. Tumor invasion into muscular vessels is associated with shorter DFS and OS and is an independent prognostic factor for both DFS and OS in our treated patient population. Therefore, tumor invasion into muscular vessels plays an important role in tumor progression and prognosis in patients with PDAC who have received neoadjuvant therapy and undergone PD.
